CN106932587B - Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient - Google Patents

Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient Download PDF

Info

Publication number
CN106932587B
CN106932587B CN201511020625.5A CN201511020625A CN106932587B CN 106932587 B CN106932587 B CN 106932587B CN 201511020625 A CN201511020625 A CN 201511020625A CN 106932587 B CN106932587 B CN 106932587B
Authority
CN
China
Prior art keywords
psg3
cancer
detection
protein
liver cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201511020625.5A
Other languages
Chinese (zh)
Other versions
CN106932587A (en
Inventor
肖汀
程书钧
陈实平
高燕宁
张开泰
冯林
郭宏林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Hospital and Institute of CAMS and PUMC
Original Assignee
Cancer Hospital and Institute of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Hospital and Institute of CAMS and PUMC filed Critical Cancer Hospital and Institute of CAMS and PUMC
Priority to CN201511020625.5A priority Critical patent/CN106932587B/en
Priority to PCT/CN2016/081858 priority patent/WO2017113565A1/en
Publication of CN106932587A publication Critical patent/CN106932587A/en
Application granted granted Critical
Publication of CN106932587B publication Critical patent/CN106932587B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses one kind being based on protein label PSG3 auxiliary diagnosis cancers, the especially kit of liver cancer and colon cancer.Claimed application of the product in preparing for the kit of diagnosing liver cancer and colon cancer for detecting protein PSG3.In the present invention, inventor is found that the presence of protein marker PSG3 in liver cancer and peripheral blood of patients with colonic cancer for the first time, and finding that the concentration of protein marker PSG3 in liver cancer and peripheral blood of patients with colonic cancer is higher than healthy person, i.e. protein marker PSG3 has the value of auxiliary diagnosis liver cancer and colorectal cancer patients.The present invention is of great significance to the auxiliary diagnosis of liver cancer and colon cancer.

Description

Examination based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient Agent box
Technical field
The present invention relates to a kind of applications of protein marker PSG3 in auxiliary diagnosis liver cancer or alimentary canal patient, and system Application in standby corresponding detection kit.
Background technology
Primary carcinoma of liver is the 6th, the whole world, Chinese 3rd most common cancer.According to International Cancer Research Center (IARC) Estimation, global onset of liver cancer number is 56.4 ten thousand people within 2000, wherein about 55% is happened at China, i.e. Chinese onset of liver cancer 30.6 ten thousand People, PLC mortality 30.0 ten thousand account for the second of China's Tumor of Residents death.Belong to middle and advanced stage when symptom occurs in liver cancer, after excision more Recurrence and metastasis rate is high.Therefore, the early diagnosis of liver cancer is to extending the life span of patient and reducing mortality of liver cancer with important Meaning.
Currently, imaging diagnosis, cell and histodiagnosis and chemical diagnosis are three big main methods of diagnosing tumor.Shadow It plays an important role, but is all had in diagnosis of small hepatic cell carcinoma and the good Malignant Nodules of differentiation certain in diagnosing cancer of liver as learning diagnosis Limitation.Ultrasonic examination or CT positive findings, it is horizontal higher than 400ng/ in conjunction with serum alpha-fetoprotein (α-fetoprotein, AFP) The testing result of ml can make liver cancer and make a definite diagnosis.But usually when these conditions all meet, treatment has been had already passed by most Good opportunity.Either ultrasonic examination, CT scan or nuclear magnetic resonance have certain limitation, especially to the identification of small lesion It is cirrhotic nodule on imageology with microhepatia cancerous node there are many similarity.Therefore, although Imaging Technology obtains Huge progress, but the molecular marker in conjunction with liver cancer is clinically still needed to, in more complicated case by good pernicious hepatopathy It distinguishes.In addition, the clinical stages and tumor size of tumour are the determinants of liver cancer treatment effect, and therefore, tumor-marker Object can be additionally used in the generaI investigation of liver cancer population at risk (such as HBV chronic carriers and liver cirrhosis patient).
The most common marker of diagnosing cancer of liver is alpha-fetoprotein (AFP) at present, the number before symptom and Imageology occur The moon may occur in which exception.AFP contents are generally less than 10ng/ml in normal human serum.When the diagnostic value of AFP is set to 20ng/ml, Its sensibility is 50~60%, but in the smaller case of tumour, and sensibility significantly reduces, and has been reported that only 40%.Individually make Another problem for using AFP as diagnosing cancer of liver marker is a lack of specificity, considerable chronic hepatitis patient especially In liver cirrhosis patient, AFP contents also reach 20-200ng/ml.It is now recognized that the marker that can be diagnosed with AFP complementations has AFP heterogeneous Body, gamma glutamyltransferase isodynamic enzyme II and abnormal prothrombin etc., but due to they on sensibility and specificity not The very complicated of foot and detection method makes it rest on laboratory research level always, fails to be converted to routine clinical inspection Project.Therefore, new tumor cells marker is explored, and establishes corresponding detection method easy to spread, is still current liver One of the important topic of cancer research field.
Equally, tumor in digestive tract is also to lead to dead one of Etiological in China.Colorectal cancer onset therein is hidden It hides, early stage, and progression of the disease was slower often without apparent clinical symptoms, mostly to middle evening when manifest symptom occurs in patient Phase.Currently, the treatment of colon is mainly based on operation, but the chemotherapy effect after colon metastasis of cancer is poor, and postoperative there are about 40% Patient is recurred, and patients with terminal survival rates are relatively low.Although having been done largely about colon cancer there are many scholar The research of molecular level, but still lack the molecular marker for effectively early diagnosing colon cancer at present.Tumor markers can To be effective as clinical diagnosis foundation, people at highest risk can be monitored, early diagnosis, guiding treatment, judge treatment curative effect, detection Recurrence and transfer, are the important Index for examination of tumor patient, with important clinical meaning.The generation of colon cancer has one early period The precancerous lesion of section time, such as polyp of colon, therefore in early detection and blocking or the development of delay cancer, have extremely important Meaning.Therefore, find find valuable tumor markers for improve tumor in digestive tract, especially colorectal cancer diagnosis and Prediction occurs, development and improvement prognosis have important Clinical significance of MG.
In human blood include abundant various cell components and molecular substance, can reflect well body different tissues and The physiology of organ, pathological state, and its sample is easy to get, and is a kind of ideal tumour non-invasive diagnosis means therefore.Therefore, Still there is the good marker of sensibility and specificity to be developed.
Pregnant differential protein 3 (Human pregnancy specific beta-1-glycoprotein 3, PSG3) is One kind being secreted into extracellular glycoprotein.Include altogether 11 albumen in PSG families, including PSG1, PSG2, PSG3 etc..PSG albumen All include generally the N-terminal structure similar with immune globulin variable region, is followed by 2-3 constant region for immunoglobulin C2 spline structure Domain and a short hydrophobic tail are located at C-terminal.PSG can be divided into 4 classes according to its structure composition, I types (N-A1-A2-B2-C), IIa types (N-A1-B2-C) and IIb types (N-A2-B2-C), type III (N-B2-C), IV types (A1-B2-C).PSG families at present Mechanism of action is unclear, under normal circumstances, great expression in the syncytionboph-oblast of placenta, outside gestational period women PSG protein contents increase in all blood, up to 200-400 μ g/ml.It is rarely reported about research of the PSG families in cancer.
428 amino acid of PSG3 length proteins, molecular weight 47,945Da, following (the SEQ ID of amino acid sequence of albumen NO:1):
MGPLSAPPCT QRITWKGLLL TALLLNFWNL PTTAQVTIEA
EPTKVSKGKD VLLLVHNLPQ NLAGYIWYKG QMKDLYHYIT
SYVVDGQIII YGPAYSGRET VYSNASLLIQ NVTREDAGSY
TLHIVKRGDG TRGETGHFTF TLYLETPKPS ISSSNLYPRE
DMEAVSLTCD PETPDASYLW WMNGQSLPMT HSLQLSKNKR
TLFLFGVTKY TAGPYECEIR NPVSASRSDP VTLNLLPKLP
KPYITINNLN PRENKDVLAF TCEPKSENYT YIWWLNGQSL
PVSPRVKRPI ENRILILPSV TRNETGPYQC EIQDRYGGIR
SYPVTLNVLY GPDLPRIYPS FTYYHSGENL YLSCFADSNP
PAEYSWTING KFQLSGQKLF IPQITTKHSG LYACSVRNSA
TGMESSKSMT VKVSAPSGTG HLPGLNPL
Research report in relation to PSGs in tumour is less.The application differential gene expression spectrum analysis such as Salahshor is found It can detect abnormal raised PSG9 transcripts in colorectal cancer, metastatic liver cancer, cervix tumor tissue, it is viscous with normal Colon and rectum Film is compared, and PSG9 raises 2 times in adenoma, and the up-regulation of colorectal cancer PSG9 abnormal expressions is mutated dependence in APC (Salahshor et al,2005).Kamarli ZP's etc. studies have shown that PSG1 albumen in bone malignant tumour patients serum Concentration increases (Kamarli et al, 2004).And it is had not been reported about researchs of the PSG3 in tumour.
Invention content
The molecule that first aspect present invention is related to detecting PSG3 albumen is being prepared for auxiliary diagnosis cancer, especially liver cancer Alimentary tract cancer patient kit or the purposes in detection reagent.
The purposes of any one according to a first aspect of the present invention, wherein the molecule of the detection PSG3 albumen is to refer to specifically Property detection PSG3 protein expressions molecule, such as can be nucleic acid, protein or compound.
The purposes of any one according to a first aspect of the present invention, wherein the protein is antibody, it can be with PSG3 albumen Specific binding, preferably monoclonal antibody.
In embodiments of the invention, the molecule of the detection PSG3 albumen is monoclonal antibody, can be with PSG3 Protein-specific combines.
In specific embodiments of the present invention, PSG3 albumen is detected using immunochemical method.
The purposes of any one according to a first aspect of the present invention, wherein the liver cancer is hepatocellular carcinoma.
The purposes of any one according to a first aspect of the present invention, wherein the alimentary tract cancer is colorectal cancer.
The purposes of any one according to a first aspect of the present invention, the kit or detection reagent are used for the inspection of plasma sample It surveys.
The purposes of any one according to a first aspect of the present invention, wherein the judgment method of the auxiliary diagnosis is, in blood plasma The content of PSG3 is higher than 551.65 μ g/ml, then person to be checked is candidate hepatocellular carcinoma or colorectal cancer patients.
The purposes of any one according to a first aspect of the present invention, wherein the molecule of the detection PSG3 albumen is also carried and be can detect Label.
The purposes of any one according to a first aspect of the present invention, wherein also containing buffer solution in the kit or detection reagent And color developing agent.
It is related to a kind of examination for auxiliary diagnosis cancer, especially liver cancer or alimentary tract cancer according to a second aspect of the present invention Agent box or detection reagent contain the product of detection marker PSG3 albumen.
It is related to a kind of examination for auxiliary diagnosis cancer, especially liver cancer or alimentary tract cancer according to a second aspect of the present invention The product of agent box or detection reagent, the detection marker PSG3 albumen is point for referring to specific detection PSG3 protein expressions Son, such as can be nucleic acid, protein or compound.
The kit or detection reagent of any one according to a second aspect of the present invention, wherein the protein is antibody, energy It is enough combined with PSG3 protein-specifics, preferably monoclonal antibody.
In embodiments of the invention, the molecule of the detection PSG3 albumen is monoclonal antibody, can be with PSG3 Protein-specific combines.
In specific embodiments of the present invention, PSG3 albumen is detected using immunochemical method.
The kit or detection reagent of any one according to a second aspect of the present invention, wherein the liver cancer is hepatocellular carcinoma, The alimentary tract cancer is colorectal cancer.
The kit or detection reagent of any one according to a second aspect of the present invention, the kit or detection reagent are used for blood The detection of slurry samples, it is preferable that the detection method is immuno-chemical method.
The kit or detection reagent of any one according to a second aspect of the present invention, wherein the judgment method of the auxiliary diagnosis For blood plasma PSG3 protein expressions are higher than 551.65 μ g/ml, then person to be checked is candidate hepatocellular carcinoma or colorectal cancer patients.
The kit or detection reagent of any one according to a second aspect of the present invention, wherein the molecule of the detection PSG3 albumen Also carry detectable label.
The kit or detection reagent of any one according to a second aspect of the present invention, wherein in the kit or detection reagent Also contain buffer solution and color developing agent.
In the present invention, wherein the molecule of the detection PSG3 albumen refers to whether detection PSG3 albumen is overexpressed Molecule, such as can be nucleic acid, protein or compound.
In the present invention, method well known in the art may be used and prepare antibody.
The method of immunoassays can be used quantitative or the presence of qualitative detection protein marker.The immunoassays are usual Binding antibody is detected including biological sample and antibody to be incubated with, and by a variety of known technologies.
In the present invention, the compound has meaning well known in the art, can be combined with PSG3 protein-specifics, And then the expression for detecting PSG3 albumen.
In the present invention, detectable mark molecule can be connected on the molecule of the detection PSG3 albumen.
In the present invention, can also include in the kit or detection reagent can be with the molecule knot of detection PSG3 albumen The molecule of conjunction, such as antibody, such as secondary antibody, the molecule can also be connected with detectable mark molecule.
In the present invention, the detectable mark molecule for example can be enzyme, fluorescein, metal ion or isotope Deng.
Description of the drawings
Figure 1A is the ROC curve that PSG3 distinguishes normal person and patients with hepatocellular carcinoma (HCC).
Figure 1B is the ROC curve that PSG3 distinguishes normal person and colorectal cancer patients (CC).
Specific implementation mode
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will Understand, the following example is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.It is not specified in embodiment specific Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is It can be with conventional products that are commercially available.
Embodiment 1 prepares the ELISA kit of PSG3 detections
Using escherichia coli prokaryotic expression PSG3 albumen, expression vector pET30a.5-6 week old BALB/c mouses are taken, profit PSG3 full-length proteins are used to prepare PSG3 antibody as antigen addition Freund's adjuvant is immune.Every mouse immune 4 times, per minor tick 2 Utilize 15-30 μ g antigen proteins every time in week, Freund's complete adjuvant utilized when first time inoculation, after utilize Freund's incomplete adjuvant three times. First three day of cell fusion selects one from three spleen cell donor mices and carries out intravenous injection PSG3 antigens and does and be further immunized. Cell fusion, hybridoma screening are according to the method (Davis et al 1982) of J.M.Davis.Simple process is as follows:Reinforce Mouse boosting cell after immune and SP2/0 myeloma cell's mixing, are slowly added into and promote 50% polyethylene glycol 0.7ml of fusion agent.37 DEG C culture 1min, 10ml IMDM culture mediums dilution, low-speed centrifugal.Then with 40ml containing 1.25% methylcellulose, 25% tire ox The IMDM culture mediums resuspension of serum, 2%HAT (containing hypoxanthine, methotrexate (MTX) and thymidine).It turns upside down mixing, It is transferred in 35mm tablets, per plate about 2ml, in 37 DEG C, 5%CO2It is cultivated in environment.7 days rear clones are transferred to 96 orifice plates, are added IMDM culture mediums containing 15% fetal calf serum and 2%HT (containing hypoxanthine and thymidine) are cultivated again.When cell melts It is right to reach 50%~70%, culture medium supernatant is collected, detects whether that there are antibody using ELISA and Western blot.
Establish the enzyme mark double antibody sandwich method of detection PSG3 antigens.Detect building for the enzyme mark double antibody sandwich method of PSG3 antigens It is vertical:Monoclonal antibody is produced first with mouse peritoneal, obtained positive hybridoma cell is injected separately into mouse peritoneal, makes it Ascites is generated, norphytane, every mouse 0.5ml are injected;Norphytane is injected after 1 week, injects hybridoma, every mouse injection 106A cell.Ascites is collected after 7-10 days respectively, purifies antibody respectively with caprylic acid-ammonium sulfate precipitation method, then use sodium periodate Antibody is carried out horseradish peroxidase-labeled (enzyme labelled antibody) by method respectively.It is coated with enzyme mark respectively with the monoclonal antibody of purifying Plate, and detection PSG3 antigens are matched with enzyme labelled antibody respectively, coated antibody P201 and the capture of enzyme mark for obtaining best pairing are anti- Body P209.Wherein coated antibody P201 and enzyme target capture antibody P209 prepare production by hybridoma cell strain P201 and P209 respectively It is raw.Hybridoma cell line P201 and P209 are common in China Committee for Culture Collection of Microorganisms on November 27th, 2015 The preservation of microorganism center, preserving number are respectively CGMCC NO.11597 and CGMCCNO.11598, and preservation address is Beijing's southern exposure Area North Star West Road No.1 institute 3.
Steps are as follows by ELISA:PSG3 coated antibodies P201 is coated with 96 hole elisa Plates, 100 holes μ l/, 4 DEG C overnight;It gets rid of Coated antibody, 0.5%PBST board-washings 3 times,2%BSA confining liquids are added,Room temperature 4 hours;It gets rid of Confining liquid, 0.5%PBST board-washings 3 times,It is separately added into PSG3 standard proteins and sample to be tested per hole in ELISA Plate, 100 holes μ l/;Add PSG3 enzyme labelled antibodies P209,100 holes μ l/, 4 DEG C overnight after mixing;Get rid of dereaction liquid, 0.5%PBST Board-washing 5 times, TMB developing solutions are added, 200 holes μ l/ are protected from light 15 minutes;2M sulfuric acid is added and terminates reaction,With detection absorbance at microplate reader OD450nm;Standard curve is drawn using the value of standard protein absorbance, and is counted Calculate the albumen concentration of PSG3 in sample to be tested.
Embodiment 2 detects the albumen concentration of PSG3 in large-scale tumor patient and normal population plasma sample
The concentration of PSG3 albumen is detected in pregnant woman's blood plasma using the ELISA kit of preparation.The sample packet of detection It includes:11 early pregnancy women (11-12 weeks), 17 Advanced pregnant women (28-38 weeks).The result of ELISA is as shown in Table 1, Albumen concentration of the PSG3 in early pregnancy women's blood plasma is significantly higher than Advanced pregnant (P<0.001).
Albumen concentration (μ g/ml) of the table 1.PSG3 in pregnant woman's blood plasma
Detect PSG3's in large-scale tumor patient and normal population plasma sample using the ELISA kit of preparation Albumen concentration.The sample of detection includes:178 hepatocellular carcinomas (Hepatocarcinoma, HCC), 121 lung cancer (Lung Cancer, LC), 159 oophoromas (Ovarian Cancer, OC), 88 colorectal cancers (Colorectal Cancer, CC), And 115 ages and the matched healthy normal person (Health Control) of sex ratio.ELISA's the results show that PSG3 It is significantly higher than Normal group (P in the plasma protein levels of hepatocellular carcinoma, colorectal cancer patients and patients with lung cancer<0.001, Table 2).
Albumen concentration (μ g/ml) of the table 2.PSG3 in each group tumor patient and normal population blood plasma
Effect of the 3 PSG3 plasma protein concentrations of embodiment in auxiliary diagnosis of hepatoma or alimentary tract cancer
When PSG3 plasma protein concentration values are 551.65 μ g/ml, the sensibility for detecting hepatocellular carcinoma is 64.2%, special The opposite sex is 74.8%, and area is 0.774,95%CI=0.719-0.828, P under ROC curve<0.001 (Figure 1A).Same group of liver Also the level of hepatocellular carcinoma marker alpha-fetoprotein (alpha-fetal protein, AFP) is had detected in carninomatosis human plasma. When the use of routine clinical detection limit value being 25ng/ml, the patient of hepatocellular carcinoma AFP negative is 107, accounts for total specimens 60.1% (107/178).And in the hepatocarcinoma patient of this 107 AFP negatives, positive (the PSG3 albumen concentration in blood plasma of PSG3> 551.65 μ g/ml) case load be 66, improve the recall rate of hepatocarcinoma patient, can clinically assist hepatocellular carcinoma sick The diagnosis of people.
When PSG3 plasma protein concentration values are 551.65 μ g/ml, the sensibility of detection colorectal cancer (n=88) is 92.0%, specificity is 74.8%, and area is 0.873,95%CI=0.819-0.828, P under ROC curve<0.001 (Figure 1B). This 88 patient's blood plasma also have detected colorectal cancer marker carcinomebryonic antigen (carcinoembryonic antigen, CEA) Protein level.When the use of routine clinical detection limit value being 5ng/ml, the patient of CEA feminine genders is 67 in colorectal cancer patients, Account for 76.1% (67/88) of total specimens.And in the Patients with Colorectal Cancer of this 67 CEA feminine genders, the PSG3 positives are (in blood plasma PSG3 albumen concentration>551.65 μ g/ml) case load be 60, significantly improve the recall rate of Patients with Colorectal Cancer, it is clinical On have preferable application prospect.
Bibliography
1.Bebo,B.F.,Jr.and G.S.Dveksler(2005)."Evidence that pregnancy specific glycoproteins regulate T-Cell function and inflammatory autoimmune disease during pregnancy."Curr Drug Targets Inflamm Allergy 4(2):231-237.
2.Blois,S.M.,et al.(2013)."Pregnancy-specific glycoprotein 1(PSG1) activates TGF-[beta]and prevents dextran sodium sulfate(DSS)-induced colitis in mice."Mucosal Immunol.
3.Camolotto,S.,et al.(2010)."Expression and transcriptional regulation of individual pregnancy-specific glycoprotein genes in differentiating trophoblast cells."Placenta 31(4):312-319.
4.Fialova,L.,et al.(1991)."[Serum levels of trophoblast-specific beta-1-globulin(SP1)and alpha-1-fetoprotein(AFP)in pregnant women with rheumatoid arthritis]."Cesk Gynekol 56(3):166-170.
5.Ha,C.T.,et al.(2005)."Binding of pregnancy-specific glycoprotein 17to CD9on macrophages induces secretion of IL-10,IL-6,PGE2,and TGF-β1." Journal of Leukocyte Biology 77(6):948-957.
6.Ha,C.T.,et al.(2008)."N-glycosylation is required for binding of murine pregnancy-specific glycoproteins 17and 19to the receptor CD9."Am J Reprod Immunol 59(3):251-258.
7.Kamarli Z.P.,et al.(2004)."Use of immunoglobulin E and pregnancy- specific beta-1-glycoprotein in differential diagnosis of bone malignancies" .Vopr Onkol.50(3):316-319.
8.Lisboa,F.A.,et al.(2011)."Pregnancy-specific Glycoprotein 1 Induces Endothelial Tubulogenesis through Interaction with Cell Surface Proteoglycans."Journal of Biological Chemistry 286(9):7577-7586.
9.Martinez,F.F.,et al.(2012)."Pregnancy-specific glycoprotein 1a activates dendritic cells to provide signals for Th17-,Th2-,and Treg-cell polarization."Eur J Immunol 42(6):1573-1584.
10.McLellan,A.S.,et al.(2005)."Structure and evolution of the mouse pregnancy-specific glycoprotein(Psg)gene locus."Bmc Genomics 6:4.
11.Motrán,C.C.,et al.(2003)."In vivo expression of recombinant pregnancy-specific glycoprotein□1a induces alternative activation of monocytes and enhances Th2-type immune response."Eur J Immunol 33(11):3007- 3016.
12.Pihl,K.,et al.(2009)."First trimester maternal serum pregnancy- specific beta-1-glycoprotein(SP1)as a marker of adverse pregnancy outcome." Prenat Diagn 29(13):1256-1261.
13.Rutherfurd,K.J.,et al.(1995)."A motif in PSG11s mediates binding to a receptor on the surface of the promonocyte cell line THP-1."Mol Endocrinol9(10):1297-1305.
14.Snyder,S.K.,et al.(2001)."Pregnancy-specific glycoproteins function as immunomodulators by inducing secretion of IL-10,IL-6 and TGF- beta1 by human monocytes."Am J Reprod Immunol 45(4):205-216.
15.Salahshor,S.,et al.(2005)."Differential gene expression profile reveals deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal carcinogenesis."Bmc Cancer 5:66.
16.Thompson,J.A.,et al.(1991)."Carcinoembryonic antigen gene family: molecular biology and clinical perspectives."J Clin Lab Anal 5(5):344-366。

Claims (8)

1. the product for detecting protein marker PSG3 concentration in plasma sample is being prepared for auxiliary diagnosis hepatocellular carcinoma With the application in the kit of colorectal cancer patients.
2. application described in claim 1, wherein the detection is carried out using immuno-chemical method.
3. application described in claim 1, wherein the product of detection protein marker PSG3 concentration is to refer to specific detection The molecule of PSG3 protein expressions.
4. the application described in claim 3, wherein the product of detection protein marker PSG3 concentration is nucleic acid, protein or chemical combination Object.
5. the application described in claim 3, wherein the molecule of the specific detection PSG3 protein expressions is antibody.
6. the application described in claim 5, wherein the antibody is monoclonal antibody.
7. the application described in claim 3 or 5, wherein the molecule of the detection PSG3 protein expressions also carries detectable mark Note.
8. the application described in claim 7, wherein also containing buffer solution and color developing agent in the kit or detection reagent.
CN201511020625.5A 2015-12-29 2015-12-29 Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient Active CN106932587B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201511020625.5A CN106932587B (en) 2015-12-29 2015-12-29 Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient
PCT/CN2016/081858 WO2017113565A1 (en) 2015-12-29 2016-05-12 Kit for auxiliary diagnosis of patient with liver cancer or digestive tract cancer based on protein marker psg3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511020625.5A CN106932587B (en) 2015-12-29 2015-12-29 Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient

Publications (2)

Publication Number Publication Date
CN106932587A CN106932587A (en) 2017-07-07
CN106932587B true CN106932587B (en) 2018-07-27

Family

ID=59442314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511020625.5A Active CN106932587B (en) 2015-12-29 2015-12-29 Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient

Country Status (1)

Country Link
CN (1) CN106932587B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110763845B (en) * 2018-07-27 2022-10-28 成都市第三人民医院 Application of ligand for detecting protein marker in preparation of product for diagnosing colon cancer and kit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389882C (en) * 2001-06-11 2007-08-07 Honda Giken Kogyo Kabushiki Kaisha Occupant restraint system
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
CA2639070A1 (en) * 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Novel tumour suppressor
CN104151407B (en) * 2014-08-01 2016-11-23 首都医科大学附属北京朝阳医院 A kind of method preparing people's pregnancy glycoprotin 9

Also Published As

Publication number Publication date
CN106932587A (en) 2017-07-07

Similar Documents

Publication Publication Date Title
BRAUNSTEIN et al. Ectopic production of human chorionic gonadotrophin by neoplasms
Liu et al. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer
JP5711196B2 (en) Use of HE4 and other biochemical markers to determine ovarian cancer
CN101449163B (en) Use of protein S100A12 as a marker for colorectal cancer
Tang et al. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection
Wang et al. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma
CN102504027A (en) Preparation of multi-epitope thymidine kinase 1 (TK1) antibody and use of multi-epitope TK1 antibody for early tumor detection and risk early warning in mass physical examination screening
Bertok et al. Identification of whole-serum glycobiomarkers for colorectal carcinoma using reverse-phase lectin microarray
Ricardo et al. Mucins MUC16 and MUC1 are major carriers of SLea and SLex in borderline and malignant serous ovarian tumors
Wang et al. Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer
CN106932587B (en) Kit based on protein marker PSG3 auxiliary diagnosis liver cancer or alimentary tract cancer patient
CN103954761B (en) For oophoroma early metaphase quick diagnosis reagent kit and detection method thereof
CA2682132C (en) Use of he4 for assessment of breast cancers
CN106928352A (en) A kind of monoclonal antibody of anti-PSG3 albumen and its hybridoma cell strain and application
EP3193173A1 (en) Serological autoantibodies as biomarker for colorectal cancer
Huang et al. Investigation of circulating antibodies to ANXA1 in breast cancer
CN103487580A (en) Application of DKK1 as diagnostic marker
ES2285469T3 (en) USE OF THE TYPE II RETINOIC ACID TRANSPORTER CELL PROTEIN (CRABP II) AS A BREAST CANCER MARKER.
CN105037534B (en) One kind detection lung cancer marker MYC epitopes amino acid sequence and application
CN108732354A (en) Applications of the RCAN1.4 as the diagnosis marker of diagnosing hepatocellular carcinoma
CN105111297B (en) One kind detection liver cancer marker IMP1 epitopes amino acid sequence and application
CN105017405B (en) One kind detection liver cancer marker BMI1 epitopes amino acid sequence and application
WO2017113565A1 (en) Kit for auxiliary diagnosis of patient with liver cancer or digestive tract cancer based on protein marker psg3
CN110456072A (en) The application of 1 α of regenerating islets original albumen and its detection method
El Hagary Study of the Serum Level of Annexin A5 as a Marker for Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis Patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant